Jeff Idle, Ph.D., FRSC, FRSB, FBPhS
Director and Endowed Professor, Arthur G. Zupko’s Systems Pharmacology and Pharmacogenomics Jeff.Idle@liu.edu
PhD, St. Mary’s Hospital Medical School, University of London, in Biochemistry
BSc, (Hons) University of Hertfordshire, in Medicinal Chemistry
BSc, University of Hertfordshire, in Applied Chemistry
Dr. Jeffrey R. Idle received a BSc in Applied Chemistry from The Hatfield Polytechnic (now University of Hertfordshire) in 1972 after completing industrial training in the development labs of Geigy Ltd (now Novartis) in Manchester in 1971. After a further period of industrial training in the pharmaceutical development labs of Wander Ltd (now Novartis) in Kings Langley in 1972, he received a BSc (First Class Hons) in Medicinal Chemistry from The Hatfield Polytechnic in 1973. He then studied under Professor R. Tecwyn Williams, FRS, the founding father of drug metabolism, receiving his PhD from the University of London in 1976. He has held the positions of Lecturer in Biochemistry, Lecturer in Biochemical Pharmacology, Wellcome Trust Senior Lecturer, and Reader in Pharmacogenetics at St. Mary’s Hospital Medical School, London. He was the co-discoverer of the first genetic polymorphism of cytochrome P450 (CYP2D6) in 1977. He was appointed to the first chair of pharmacogenetics at the University of Newcastle in 1988, was department chair and head of the School of Clinical Medical Sciences. He developed a large and active research group in Newcastle, founded the journal Pharmacogenetics while there in 1990 and the campus biotech company GenoType Ltd, the first company to provide genetic services to the pharmaceutical industry and the National Institutes of Health. In 1995, he moved to the Norwegian University of Science and Technology in Trondheim as Professor in Medicine and Molecular Biology, then to Charles University in Prague, Czech Republic as Visiting Professor in Pharmacology and the University of Bern, Switzerland as Visiting Professor in Clinical Pharmacology and Senior Research Fellow, until his appointment at LIU in January 2018. Professor Idle is a Fellow of the Royal Society of Chemistry, the Royal Society of Biology, and the British Pharmacological Society. His research history spans drug metabolism, pharmacogenetics, metabolomics, and lipidomics, particularly as applied to medicine.
My research career has primarily been concerned with metabolism, both the conversion of xenobiotics and endogenous molecules to metabolic products and the biological consequences both of these conversions and the failure to perform such metabolic transformations. This research has impacted upon virtually all medical specialties and many common diseases, with important applications to the practice of pharmacy.
Beyoğlu D, Zhou Y, Chen C, Idle JR. Mass isotopomer-guided decluttering of metabolomic data to visualize endogenous biomarkers of drug toxicity. Biochem Pharmacol 2018; 156: 491-500
Golla S, Golla JP, Krausz KW, Mann SK, Simillion C, Beyoğlu D, Idle JR, Gonzalez FJ. Metabolomic analysis of mice exposed to γ-irradiation reveals a systemic understanding of total body radiation exposure. Radiat Res 2017; 187: 612-629.
Pabst T, Kortz L, Fiedler GM, Ceglarek U, Idle JR, Beyoğlu D. The plasma lipidome in acute myeloid leukemia at diagnosis in relation to clinical disease features. BBA Clin 2017; 7: 105-114.
Keogh A, Şenkardeş S, Idle JR, Küçükgüzel ŞG, Beyoğlu D. A novel antihepatitis C virus and antiproliferative agent alters metabolic networks in hepatoma cells. Metabolites 2017; Jun 2;7(2). pii: E23. doi: 10.3390/metabo7020023
Patel DP, Krausz KW, Xie X, Beyoğlu D, Gonzalez FJ, Idle JR. Metabolic profiling of energy metabolism in high-fat diet-fed obese mice. PLoS ONE 2017; 12:e0177953. doi: 10.1371/journal.pone.0177953. eCollection 2017.
Simillion C, Semmo N, Idle JR, Beyoğlu D. Robust regression analysis of GCMS data reveals differential rewiring of metabolic networks in hepatitis B and C patients. Metabolites 2017; 7: 51; doi:10.3390/metabo7040051.
Armstrong M, Daly AK, Cholerton S, Bateman DN, Idle JR. Mutant debrisoquine hydroxylation genes in Parkinson's disease. Lancet 1992; 339: 1017-1018.
Johnson CH, Slanař O, Krausz KW, Kang DW, Patterson AD, Kim JH, Luecke H, Gonzalez FJ, Idle JR. Novel metabolites and roles for α-tocopherol in humans and mice discovered by mass spectrometry-based metabolomics. Am J Clin Nutr 2012; 96: 818-830. PMCID: PMC3441109
Johnson CH, Patterson AD, Krausz KW, Kalinich JF, Tyburski JB, Kang DW, Lueke H, Gonzalez FJ, Blakely WF, Idle JR. Radiation metabolomics. 5. Identification of urinary biomarkers of ionizing radiation exposure in non-human primates by MS-based metabolomics. Radiat Res 2012; 178: 328-340. PMCID: PMC3498937
Li F, Patterson AD, Krausz KW, Dick B, Frey FJ, Gonzalez FJ, Idle JR. Metabolomics reveals the metabolic map of procainamide in humans and mice. Biochem Pharmacol 2012; 83: 1435-1444. PMCID: PMC3665348
Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977; 2: 584-586.
Idle JR, Mahgoub A, Lancaster R, Smith RL. Hypotensive response to debrisoquine and hydroxylation phenotype. Life Sci 1978; 22: 979-983.
Evans DAP, Mahgoub A, Sloan TP, Idle JR, Smith RL. A family and population study of the genetic polymorphism of debrisoquine oxidation in a British white population. J Med Genet 1980; 17: 102-105. PMCID: PMC1048511
Daly, AK, Armstrong M, Monkman SC, Idle ME, Idle JR. The genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P450IID6) phenotypes. Pharmacogenetics 1991; 1: 33-41.
Løvlie R, Daly AK, Molven A, Idle JR, Steen VM. Ultrarapid metabolizers of debrisoquine: Characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Lett 1996; 392: 30-34.
Ayesh R, Idle JR, Ritchie JC, Crothers MJ, Hetzel MR. Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature 1984; 312: 169-170.
Idle JR, Mahgoub A, Sloan TP, Smith RL, Mbanefo CO, Bababunmi EA. Some observations of the oxidative phenotype status of Nigerian patients presenting with cancer. Cancer Lett 1981; 11: 331-338.
Caporaso N, Hayes RB, Dosemeci M, Hoover R. Ayesh R, Hetzel M, Idle J. Lung cancer risk, occupational exposure and the debrisoquine metabolic phenotype. Cancer Res 1989; 49: 3675-3679.
Oates NS, Shah RR, Idle JR, Smith RL. Genetic polymorphism of phenformin 4-hydroxylation. Clin Pharmacol Ther 1982; 32: 81-89.
Al-Waiz M, Ayesh R, Mitchell SC, Idle JR, Smith RL. A genetic polymorphism of the N-oxidation of trimethylamine in man. Clin Pharmacol Ther 1987; 42: 588-594.
Furuya H, Gregory W, Taber H, Gonzalez FJ, Idle JR. Genetic Polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation. Pharmacogenetics 1995; 5: 389-392.
Fernandez-Salguero P, Hoffman SMG, Cholerton S, Mohrenweiser H, Raunio H, Pelkonen O, Huang J-D, Evans WE, Idle JR and Gonzalez FJ. A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. Am J Hum Genet 1995; 57: 651-660. PMCID: PMC1801261
Giri S, Idle JR, Chen C, Zabriskie TM, Krausz KW, Gonzalez FJ. A metabolomic approach to the metabolism of the areca nut alkaloids arecoline and arecaidine in the mouse. Chem Res Toxicol 2006; 19: 818-827. PMCID: PMC1482804
Zhen Y, Krausz KW, Chen C, Idle JR, Gonzalez FJ. Metabolomic and genetic analysis of biomarkers for PPARα expression and activation. Mol Endocrinol 2007; 21: 2136-2151. PMCID: PMC2084472
Patterson AJ, Li H, Eichler G, Krausz KW, Weinstein JN, Fornace AJ, Gonzalez FJ, Idle JR. UPLC-ESI-TOFMS-based metabolomics and Gene Expression Dynamics Inspector self-organizing metabolomic maps as tools for understanding the cellular response to ionizing radiation. Anal Chem 2008; 80: 665-674. PMCID: 2254319
Chen C, Shah Y, Morimura K, Krausz KW, Miyazaki M, Ntambi JM, Idle JR, Gonzalez FJ. Metabolomics reveals that hepatic stearoyl-CoA desaturase 1 downregulation exacerbates inflammation and acute colitis. Cell Metab 2008; 7: 135-147. PMCID: PMC2276699
Join the LIU Community!
We can't wait to welcome you to Shark Nation.
The application process is quick and easy, but if you have
any questions, our admissions counselors are here to help.